HC Wainwright & Co. Maintains Buy on Roivant Sciences, Raises Price Target to $41

Benzinga Newsdesk www.benzinga.com Positive 71.4%

Neg 0% Neu 0% Pos 71.4%

HC Wainwright & Co. analyst Douglas Tsao maintains Roivant Sciences (NASDAQ:ROIV) with a Buy and raises the price target from $34 to $41.